Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report

(1) Background: Hypofractionated stereotactic radiotherapy (HSRT) and anti-vascular endothelial growth factor (VEGF) antibodies have been reported to have a promising survival benefit in recent studies. Anlotinib is a new oral VEGF receptor inhibitor. This report describes our experience using HSRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yun, Li, Jing, Gong, Xiu, Zhu, Huaguang, Li, Chao, Mei, Guanghai, Liu, Xiaoxia, Pan, Li, Dai, Jiazhong, Wang, Yang, Wang, Enmin, Liu, Ying, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032064/
https://www.ncbi.nlm.nih.gov/pubmed/35448002
http://dx.doi.org/10.3390/brainsci12040471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032064/
https://www.ncbi.nlm.nih.gov/pubmed/35448002
http://dx.doi.org/10.3390/brainsci12040471

Ejemplares similares